Home Featured Page 186

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Could the Sonoran Desert Toad Cure Narcissism?

Mydecine Announces Reverse Stock-Split

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and...

PT309 – Jon Dennis, Esq. – Oregon’s Measure 109 and the...

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by...

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule...

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.